Jounce Therapeutics Inc (JNCE) CEO and President Richard /ca/ Murray Sold $838,011 of Shares
- By insider
CEO and President of Jounce Therapeutics Inc (30-Year Financial, Insider Trades) Richard /ca/ Murray (insider trades) sold 86,482 shares of JNCE on 01/20/2021 at an average price of $9.69 a share. The total sale was $838,011.
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in transforming the treatment pf cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Jounce Therapeutics Inc has a market cap of $452.315 million; its shares were traded at around $11.350000 with and P/S ratio of 2.63. GuruFocus has detected 2 severe warning signs with Jounce Therapeutics Inc. .
CEO Recent Trades:
CEO and President Richard /ca/ Murray sold 86,482 shares of JNCE stock on 01/20/2021 at the average price of $9.69. The price of the stock has increased by 17.13% since.
CEO and President Richard /ca/ Murray sold 21,999 shares of JNCE stock on 01/08/2021 at the average price of $6.89. The price of the stock has increased by 64.73% since.
CFO Recent Trades:
CFO and Treasurer Kimberlee C Drapkin sold 5,827 shares of JNCE stock on 01/08/2021 at the average price of $6.89. The price of the stock has increased by 64.73% since.
Directors and Officers Recent Trades:
Chief Medical Officer Elizabeth Trehu sold 5,298 shares of JNCE stock on 01/08/2021 at the average price of $6.89. The price of the stock has increased by 64.73% since.
Chief Business Officer Hugh M Cole sold 6,219 shares of JNCE stock on 01/08/2021 at the average price of $6.89. The price of the stock has increased by 64.73% since.
For the complete insider trading history of JNCE, click here
.This article first appeared on GuruFocus.
